Inner Cosmos Completes FDA Early Feasibility Study

🎉 Read the full Forbes coverage here 🎉

Contact Us

Newsroom

Clinical Trial Update | FDA Early Feasibility Study Completion

  • By By Dr. Darin Dougherty, Chief Medical Officer

I am pleased to share a clinical update regarding the Early Feasibility Study (EFS) evaluating the Inner Cosmos minimally invasive […]

Read More>>

Inner Cosmos Appoints John Freund to Board of Directors and Greg Schulte as Advisory CTO to Advance Psychiatric BCI for Depression

  • By Inner Cosmos

Inner Cosmos Inner Cosmos, a neurotechnology company pioneering psychiatric treatment with a minimally invasive BCI for refractory depression, today announced […]

Read More>>

Clinical Study Update | Q2 2025

  • By Dr. Darin Dougherty, Chief Medical Officer

Interim 36-Month Outcomes from Inner Cosmos’ Psychiatric Neurostimulation Study in Treatment-Resistant Depression Inner Cosmos is pleased to share new interim […]

Read More>>